Ezetimibe - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for ezetimibe and what is the scope of freedom to operate?
Ezetimibe
is the generic ingredient in five branded drugs marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms Co, Apotex, Aurobindo Pharma, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Ohm Labs Inc, Orient Pharma, Rising, Sandoz, Sciegen Pharms Inc, Teva Pharms Usa, Watson Labs Inc, Zydus Pharms, Organon, Althera Pharms, Ani Pharms, Aurobindo Pharma Usa, and Dr Reddys Labs Sa, and is included in twenty-six NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Ezetimibe has two hundred and thirty-five patent family members in thirty-eight countries.
There are twenty-four drug master file entries for ezetimibe. Twenty-eight suppliers are listed for this compound.
Summary for ezetimibe
International Patents: | 235 |
US Patents: | 3 |
Tradenames: | 5 |
Applicants: | 21 |
NDAs: | 26 |
Drug Master File Entries: | 24 |
Finished Product Suppliers / Packagers: | 28 |
Raw Ingredient (Bulk) Api Vendors: | 113 |
Clinical Trials: | 349 |
Patent Applications: | 6,424 |
Drug Prices: | Drug price trends for ezetimibe |
Drug Sales Revenues: | Drug sales revenues for ezetimibe |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ezetimibe |
What excipients (inactive ingredients) are in ezetimibe? | ezetimibe excipients list |
DailyMed Link: | ezetimibe at DailyMed |
Recent Clinical Trials for ezetimibe
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Nykøbing Falster County Hospital | N/A |
Steno Diabetes Center Odense | N/A |
Hillerod Hospital, Denmark | N/A |
Pharmacology for ezetimibe
Drug Class | Dietary Cholesterol Absorption Inhibitor |
Physiological Effect | Decreased Cholesterol Absorption |
Medical Subject Heading (MeSH) Categories for ezetimibe
Anatomical Therapeutic Chemical (ATC) Classes for ezetimibe
US Patents and Regulatory Information for ezetimibe
Expired US Patents for ezetimibe
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Organon | ZETIA | ezetimibe | TABLET;ORAL | 021445-001 | Oct 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Organon | ZETIA | ezetimibe | TABLET;ORAL | 021445-001 | Oct 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Organon | ZETIA | ezetimibe | TABLET;ORAL | 021445-001 | Oct 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Organon | ZETIA | ezetimibe | TABLET;ORAL | 021445-001 | Oct 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Organon | ZETIA | ezetimibe | TABLET;ORAL | 021445-001 | Oct 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ezetimibe
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 100883461 | ⤷ Sign Up | |
Mexico | PA03005671 | 2-AZETIDINONAS SUSTITUIDAS CON AZUCARES UTILES COMO AGENTES HIPOCOLESTEROLEMICOS. (SUGAR-SUBSTITUTED 2-AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS.) | ⤷ Sign Up |
Norway | 20033357 | ⤷ Sign Up | |
Japan | 2012087149 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATORS AND STEROL ABSORPTION INHIBITORS AND TREATMENTS FOR VASCULAR INDICATIONS | ⤷ Sign Up |
New Zealand | 545332 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | ⤷ Sign Up |
European Patent Office | 1810693 | ⤷ Sign Up | |
Turkey | 200402758 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ezetimibe
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0720599 | 2003/014 | Ireland | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: 1091/1/1 00040127; FIRST REGISTRATION NO/DATE: EU: DE 54489.00.00 54486.00.00 54488.00.00 54487.00.00 20021017; PAEDIATRIC INVESTIGATION PLAN: P/0061/2012 |
0720599 | CR 2014 00048 | Denmark | ⤷ Sign Up | PRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724 |
0720599 | 03C0028 | France | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017 |
0720599 | 300689 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
0720599 | CR 2014 00050 | Denmark | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
0720599 | SPC/GB03/023 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: DE 54486.00.00 20021017; DE 54488.00.00 20021017; DE 54487.00.00 20021017; DE 54489.00.00 20021017; UK PL 19945/0001 20030404; UK PL 19945/0002 20030404 |
0720599 | C300172 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN SIMVASTATINE; NAT. REGISTRATION NO/DATE: RVG 30927RVG 30928RVG 30929RVG 30930 2004221122; FIRST REGISTRATION: 58874.00.0058874.01.0058874.02.0058874.03.0058878.00.0058878.01.0058878.02.0058878.03.0058866.00.0058866.01.0058866.02.0058866.03.0058870.00.0058870.01.0058870.02.0058870.03.00 2004020402 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.